Traws Pharma (TRAW) Stock Statistics & Valuation Metrics

Traws Pharma has a market cap or net worth of $12.64M. The enterprise value is -$4.47M.

Traws Pharma has 7,063,829 shares outstanding. The number of shares has decreased by -2.65% in one year.

Traws Pharma’s return on equity (ROE) is 1.73 and return on invested capital (ROIC) is -367.47%.

The current PE Ratio of Traws Pharma is 0.1. Traws Pharma’s PEG ratio is ―.

In the last 12 months, Traws Pharma had revenue of 226.00K and earned -54.67M in profits. Earnings per share was -35.21.

In the last 12 months, operating cash flow was -11.43B and capital expenditures 0.00, giving a free cash flow of -11.43B billion.

Traws Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Traws Pharma upcoming earnings date is Nov 13, 2025, Before Open (Confirmed).

Traws Pharma as a current ratio of 2.16, with Debt / Equity ratio of 0.00%

In the past 12 months, Traws Pharma has paid 0.00 in taxes.

Traws Pharma EV to EBITDA ratio is 0.05, with an EV/FCF ratio of 0.25.

Traws Pharma has $13.08M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$13.08M billion.

Gross margin is 99.83%, with operating margin of -21835.40%, and net profit margin of -24192.04%.

The average price target for Traws Pharma is $6.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy